To determine whether the tumor formation of glioblastoma oncogenicity is dependent upon CHL1, we reduced CHL1 expression using CHL1-siRNA combined with EntransterTM-in vivo, which was intratumorally injected to specifically knockdown endogenous CHL1 expression in vivo. The gene discussed is CHL1; the disease is neoplasm.